Zusammenfassung
Hintergrund
Die Grenzbereiche der Lebertransplantation liegen vor allem in der Ausweitung der Indikation (hepatozelluläres Karzinom, [perihiläres] Cholangiokarzinom, Empfänger mit gravierenderen Nebendiagnosen bzw. „weichen“ Kontraindikationen) und technisch anspruchsvollen Rekonstruktionsverfahren der vaskulären Strukturen (bei Portalvenenthrombose bzw. schwieriger arterieller Anschlussmöglichkeit) sowie einer Erweiterung des Spenderpools mit suboptimalen Organen (ältere Spender, steatotische Lebern).
Methoden
Anhand persönlicher Erfahrungen im klinischen Alltag und entsprechender Literaturrecherche legen wir in diesem Artikel die aktuelle Situation dar.
Ergebnisse
In Deutschland zeigt sich eine deutliche Abnahme des 1‑Jahres-Überlebens. Der Anteil an „schwer vermittelbaren“ („marginalen“) Spenderorganen verhält sich dabei reziprok zum massiv erniedrigten Spenderaufkommen und parallel zur steigenden Wartelistenmortalität (WL). Gleichzeitig nimmt der Anteil an stationären WL-Patienten mit Mehrorganversagen zu.
Schlussfolgerung
Eine ergebnisorientierte und -kontrollierte Lebertransplantation erlaubt heutzutage kaum noch ein Vordringen in ehemalige Grenzbereiche. Solange sich die aktuellen Bedingungen nicht ändern, wird ein Verschieben der Grenzen des chirurgisch Machbaren kaum möglich sein. Vielmehr kann in der aktuellen Situation durch restriktivere Indikationsstellung und Organakzeptanz nur versucht werden, die ehemals erreichten Erfolge mit exzellentem Kurz- und Langzeitüberleben (1-Jahres-Überleben von 90 %, 20-Jahres-Überleben von 50 %) wieder zu ermöglichen.
Abstract
Background
The frontiers in liver transplantation are intrinsically expansions of indications, e.g. hepatocellular carcinoma and (perihilar) cholangiocarcinoma, recipients with more severe concomitant diagnoses or “soft” contraindications and technically demanding reconstruction procedures of vascular structures (for portal vein thrombosis or aorto-hepatic conduits). In addition, an extension of the donor pool with suboptimal donor organs (old donors and steatotic livers) is of interest.
Methods
This article presents the current situation based on personal experiences in daily practice and an appropriate literature review.
Results
A significant reduction of 1‑year patient survival has been reported in Germany. The percentage of so-called marginal donor organs is inversely proportional to the very low donation rate and parallel to the waiting list mortality. Simultaneously, the proportion of inpatients with multiple organ failure is rising.
Conclusion
Results-oriented and controlled liver transplantation currently prohibits making inroads into the previously intrinsic frontiers. As long as the current circumstances do not change, a shift in the intrinsic frontiers of that which is surgically feasible will not be possible. The current situation forces the transplant surgeon to apply a more restrictive indications and organ acceptance policy. With this approach we can try to regain the previously excellent short- and long-term results of a 1‑year survival of 90% and a 20-year survival of 50%.
Literatur
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289
Bundesärztekammer (2017) Richtlinien zur Organtransplantation. Dtsch Arztebl 114:A 2019
Cardoso FS, Karvellas CJ, Kneteman NM, Meeberg G, Fidalgo P, Bagshaw SM (2015) Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score 〉/= 40: a retrospective cohort study. Can J Gastroenterol Hepatol 29:185–191
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Baillieres Clin Gastroenterol 143:88–98e3 (quiz e14)
Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK (2012) Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 56:972–981
De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ (2000) Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 6:309–316
DSO (2017) DSO Jahresbericht. https://www.dso.de/uploads/tx_dsodl/JB_2017_web_01.pdf. Zugegriffen: 15. September 2018
Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O (2002) Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant 2:934–938
Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ (2010) Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 16:83–90
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255
Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F (2005) Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 54:691–697
Francoz C, Valla D, Durand F (2012) Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 57:203–212
Gayowski TJ, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, Wagener M, Singh N, Yu VL, Fung JJ, Starzl TE (1996) A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 60:333–338
Gonzalez Martinez S, Molina RA, Becerra Massare A, Muffak Granero K, Villegas Herrera T, Villar Del Moral JM, Fundora Suarez Y (2018) Liver transplantation in recipients with high model for end-stage liver disease score. Transplant Proc 50:595–597
Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB (2013) Liver transplantation for perihilar cholangiocarcinoma. Dig Dis 31:126–129
Gotthardt DN, Weiss KH, Rupp C, Bode K, Eckerle I, Rudolph G, Bergemann J, Kloeters-Plachky P, Chahoud F, Buchler MW, Schemmer P, Stremmel W, Sauer P (2013) Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy 45:890–896
Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB (2004) Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 24:201–207
Henson JB, Patel YA, King LY, Zheng J, Chow SC, Muir AJ (2017) Outcomes of liver retransplantation in patients with primary sclerosing cholangitis. Liver Transpl 23:769–780
Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H (2018) Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. J Hepatol 69:982–984
Hessheimer AJ, Cardenas A, Garcia-Valdecasas JC, Fondevila C (2016) Can we prevent ischemic-type biliary lesions in donation after circulatory determination of death liver transplantation? Liver Transpl 22:1025–1033
Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, Tzakis AG (2014) When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg 259:760–766
IQTIG (2017) Qualitätsreport. https://iqtig.org/downloads/berichte/2017/IQTIG_Qualitaetsreport-2017_2018_09_21.pdf. Zugegriffen: 15. September 2018
Kim H, Lee KW, Yi NJ, Lee HW, Choi Y, Suh SW, Jeong J, Suh KS (2015) Outcome and technical aspects of liver retransplantation: analysis of 25-year experience in a single major center. Transplant Proc 47:727–729
Krenzien F, Schmelzle M, Struecker B, Raschzok N, Benzing C, Jara M, Bahra M, Ollinger R, Sauer IM, Pascher A, Pratschke J, Andreou A (2018) Liver transplantation and liver resection for cirrhotic patients with Hepatocellular carcinoma: comparison of long-term survivals. J Gastrointest Surg 22:840–848
Lim C, Salloum C, Compagnon P, Laurent A, Azoulay D (2015) Liver transplantation and portal vein thrombosis: an unfinished saga. Ann Surg 262:e90
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Metroticket Investigator Study G (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43
Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A (2018) Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Baillieres Clin Gastroenterol 154:128–139
Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, Mulligan D, Gonwa TA, Klintmalm GB (2002) Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg 235:292–296
Muller X, Marcon F, Sapisochin G, Marquez M, Dondero F, Rayar M, Doyle MMB, Callans L, Li J, Nowak G, Allard MA, Jochmans I, Jacskon K, Beltrame MC, van Reeven M, Iesari S, Cucchetti A, Sharma H, Staiger RD, Raptis DA, Petrowsky H, de Oliveira M, Hernandez-Alejandro R, Pinna AD, Lerut J, Polak WG, de Santibanes E, de Santibanes M, Cameron AM, Pirenne J, Cherqui D, Adam RA, Ericzon BG, Nashan B, Olthoff K, Shaked A, Chapman WC, Boudjema K, Soubrane O, Paugam-Burtz C, Greig PD, Grant DR, Carvalheiro A, Muiesan P, Dutkowski P, Puhan M, Clavien PA (2018) Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. Ann Surg 267:419–425
Pichlmayr R, Weimann A, Tusch G, Schlitt HJ (1997) Indications and role of liver transplantation for malignant tumors. Oncologist 2:164–170
Ravaioli M, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Cucchetti A, Pinna AD (2011) Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg 253:378–384
Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168–2179
Reese T, Raptis DA, Oberkofler CE, de Rougemont O, Gyori GP, Gosteli-Peter M, Dutkowski P, Clavien PA, Petrowsky H (2018) A systematic review and meta-analysis of rescue revascularization with arterial conduits in liver transplantation. Am J Transplant. https://doi.org/10.1111/ajt.15018
Sapisochin G, Bruix J (2017) Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 14:203–217
Sapisochin G, Fidelman N, Roberts JP, Yao FY (2011) Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 17:934–942
Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, Castroagudin JF, Varo E, Lopez-Andujar R, Palacios F, Sanchez AG, Perez B, Guiberteau A, Blanco G, Gonzalez-Dieguez ML, Rodriguez M, Varona MA, Barrera MA, Fundora Y, Ferron JA, Ramos E, Fabregat J, Ciria R, Rufian S, Otero A, Vazquez MA, Pons JA, Parrilla P, Zozaya G, Herrero JI, Charco R, Bruix J (2014) “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant 14:660–667
Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, Lopez-Andujar R, Palacios F, Ramos E, Fabregat J, Castroagudin JF, Varo E, Pons JA, Parrilla P, Gonzalez-Dieguez ML, Rodriguez M, Otero A, Vazquez MA, Zozaya G, Herrero JI, Antolin GS, Perez B, Ciria R, Rufian S, Fundora Y, Ferron JA, Guiberteau A, Blanco G, Varona MA, Barrera MA, Suarez MA, Santoyo J, Bruix J, Charco R (2014) Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 259:944–952
Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCAIC (2016) Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 64:1178–1188
Schlitt HJ, Loss M, Scherer MN, Becker T, Jauch KW, Nashan B, Schmidt H, Settmacher U, Rogiers X, Neuhaus P, Strassburg C (2011) Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres. Z Gastroenterol 49:30–38
Schmelzle M, Krenzien F, Schoning W, Pratschke J (2018) Treatment of hepatocellular carcinoma in the cirrhotic and non-cirrhotic liver. Chirurg. https://doi.org/10.1007/s00104-018-0690-6
Schoening W, Helbig M, Buescher N, Andreou A, Schmitz V, Bahra M, Puhl G, Pascher A, Pratschke J, Seehofer D (2016) Eurotransplant donor-risk-index and recipient factors: influence on long-term outcome after liver transplantation—a large single-center experience. Clin Transplant 30:508–517
Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, Puhl G, Seehofer D, Neuhaus P (2013) Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant 13:2384–2394
Schulte K, Borzikowsky C, Rahmel A, Kolibay F, Polze N, Frankel P, Mikle S, Alders B, Kunzendorf U, Feldkamp T (2018) Decline in organ donation in Germany. Dtsch Arztebl Int 115:463–468
Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr., McCashland T, Sorrell M, Tempero M, Langnas A (2002) Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2:774–779
Terrault NA, Pageaux GP (2018) A changing landscape of liver transplantation: king HCV is dethroned, ALD and NAFLD take over! J Hepatol 69:767–768
Weismuller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP (2011) Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany—limitations of the „sickest first“-concept. Transpl Int 24:91–99
Xia VW, Taniguchi M, Steadman RH (2008) The changing face of patients presenting for liver transplantation. Curr Opin Organ Transplant 13:280–284
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403
Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J (2000) Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 69:1873–1881
Zarrinpar A, Hong JC (2012) What is the prognosis after retransplantation of the liver? Adv Surg 46:87–100
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
W. Schöning, R. Öllinger, M. Schmelzle und J. Pratschke geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Schöning, W., Öllinger, R., Schmelzle, M. et al. Grenzbereiche der Lebertransplantation in Indikation und Technik. Chirurg 90, 102–109 (2019). https://doi.org/10.1007/s00104-018-0761-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-018-0761-8